Verification of
autoantibody profiles on suspension bead arrays with selected antigens.
University of Michigan - Ann Arbor
Autoantibody profiles for cancer diagnosis, prognosis, and therapy
Our guest published a historic paper less than one month ago (available here), describing the first comprehensive study of an individual, combining genomic (genome sequence), transcriptomic (genes turned on / off), proteomic (the total complement of proteins - or protein profiles), metabolomic (complete metabolic analysis), and
autoantibody profiles.
In a recent publication, CDI's technology was also used to develop
an autoantibody profile for neuropsychiatric lupus (2), a valuable diagnostic tool for a disease that typically lacks clear clinical signs.
Hu C et al. (2015)
Autoantibody Profiling on Human Proteome Microarray for Biomarker Discovery in Cerebrospinal Fluid and Sera of Neuropsychiatric Lupus.
Not exact matches
Profiling the
autoantibody repertoire in plasma, serum or CSF by screening on microarrays of randomly selected antigens.
The Autoimmunity
profiling facility provides infrastructure and technologies for analysis of the
autoantibody repertoire in body fluids and antibody validation using custom designed protein and peptide arrays.
The changes in the serum thyroid
autoantibodies, antithyroglobulin (TgAb) and antithyroid - peroxidase (TPOAb), lipid
profile, and thyroid volume following L - thyroxine (L - T4) therapy is still a controversial matter.
The phenotypic test to identify affected dogs is thyroglobulin
autoantibodies (TgAA).1 Based on thyroid
profiles run at the Michigan State University DCPAH, 10.7 % of 55,053 mixed breed dogs tested affected for autoimmune thyroiditis.